The COVID-19 pandemic consumed most of 2020. While it was the big story last year, it wasn't the only story. Precision's Dan Danielson and other experts weigh in on the oversized impact of COVID-19 on the pharma industry, and other trends from 2020.
Value-based care has been replacing the traditional fee-for-service model in the United States. Value-based care models and population health are essential to improving health and reducing health care costs. Precision's Ryan Cox discusses how value-based payment models in chronic kidney disease can improve total cost and quality of care for patients.
An interim final rule that would require pricing drugs on the U.S. market based on their prices in certain countries is set to take effect on Jan. 1, 2021. Industry experts claim it will have little effect on bringing down prices for consumers. Precision's Ryan Cox joins other experts in discussing the far ranging impact of the new rule.
The trend of using real-world evidence (RWE) in the healthcare industry continues to grow. But perhaps it has never been more important than it is now during the current pandemic. Precisions Dan Danielson and others discuss the benefits to be gained from using RWE in the search for potential diagnostics, drugs and vaccines for COVID-19.
Many highly specialized, expensive drugs are in protected categories that must be covered. With few other options, payers are digging in with more prior authorization and other utilization management tactics. Precision's Dominic Galante weighs in on the increasingly difficult path to securing prior payer approval for high cost drugs.
The complexities and misaligned incentives within our healthcare system have affected the pace of biosimilar adoption in the US.
The gene therapy market is still in its infancy but poised for significant growth, with an approximate 25% increase in therapies in the pipeline as compared to 2018. However, the launch of a gene therapy is an event with limited case examples to follow and numerous unique considerations.
Precision's Maureen Hennessey discusses 3 crisis management-social networking strategies from the Ebola crisis that offer a playbook for addressing the current COVID-19 pandemic and infodemic, and its vaccine adoption.
The Centers for Medicare & Medicaid Services announced its third annual evaluation report of the Oncology Care Model in July 2020, covering performance periods 1-3 activities and results. Precision's Maureen Hennessey and Larry Blandford update observations from earlier reports.
The Brazilian health system, a mix of private and public payers, predominantly relies on a fee for service model. In order to meet the health care needs of a growing population but also control spending, Brazil needs to evolve its payment models toward value-based health care.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
